via University College London
The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
- ‘Robbed’: Foremans share their experience with Huntington’s diseaseon May 18, 2022 at 6:51 pm
Huntington’s disease (HD) is described as one of the cruelest diseases known to mankind; symptoms are described as having MND, Parkinson’s and Alzheimer’s ...
- Georgia Team Hope Walk held to raise awareness, funds for Huntington’s diseaseon May 15, 2022 at 8:14 pm
The Huntington’s Disease Society of America’s Georgia Chapter held the Georgia Team Hope Walk at Mason Mill Park in Decatur. Metro Atlanta joined more than 100 other cities across the nation to help ...
- Insights on the Huntington Disease Treatment Global Market to 2027 - Featuring Pfizer, Bausch Health and Dr. Reddy's Laboratories Among Otherson May 13, 2022 at 7:30 am
The "Huntington Disease Treatment Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's ...
- Global Huntington Disease Treatment Market Report (2022 to 2027) - Industry Trends, Growth, Impact of COVID-19 and Company Analysison May 12, 2022 at 2:43 am
The report provides a complete analysis of Global Huntington's Disease Treatment Industry. The global huntington's disease treatment market will reach US$ ...
- Carilion Clinic looking for Huntington’s disease patients for surveyon May 10, 2022 at 5:06 pm
Carilion Clinic is looking for people with Huntington’s disease to participate in a survey to better patients’ care. The survey will look at people’s experience with the disease, quality of life and ...
- Huntington's: A complex brain disease that affects movement, thoughts and feelingson May 10, 2022 at 10:54 am
Huntington's disease is hereditary, genetic and usually begins between the ages of 30 and 50. In Sweden, around 1,000 people have the diagnosis and several thousand live with the risk of getting the ...
- Huntington's Disease Treatment Market Share to See Modest Growth Through 2022-2030on May 10, 2022 at 1:06 am
The study on global Huntington's Disease Treatment market, offers profound understandings about the Huntington's Disease Treatment market covering all the essential aspects of the market. The report ...
- Huntington's disease: what is this rare neurodegenerative disorder?on May 9, 2022 at 9:00 am
Huntington's disease (HD) is a rare, inherited disorder that causes the progressive breakdown of nerve cells in the brain. It's a condition that's passed down in families from generation to generation ...
- bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screeningon May 8, 2022 at 11:00 pm
CAMBRIDGE, England, May 09, 2022--bit.bio, a synthetic biology company working on developing and providing every human cell type at scale, with the aim of transforming the research and medicine ...
- Huntington's Disease Newson April 30, 2022 at 5:00 pm
Feb. 16, 2022 — Huntington's, Alzheimer's, ALS, and multiple other neurodegenerative diseases share a commonality: they are all characterized by proteins (different ones for each disease ...
via Google News and Bing News